Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting cancer through simultaneous inhibition of key metabolic enzymes

ABSTRACT: This study explored the potential metabolic vulnerabilities of ovarian cancer cells in comparison to their non-oncogenically transformed precursor cells. A synthetic lethal screen with inhibitors of metabolic pathways showed that simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of tumor cells. While (R)-GNE-140 inhibits lactate dehydrogenase (LDH)A/B and thus effective glycolysis, the BMS-986205 compound, in addition to its known inhibitory activity on Indoleamine 2,3-dioxygenase (IDO1), can also restrict oxidative phosphorylation, as revealed in this study. BMS-986205, which is already in multiple phase III clinical trials, inhibits the Q site of complex I and thus ATP production through mitochondrial respiration. The energetic catastrophe caused by simultaneous interference with glycolysis and oxidative phosphorylation led to cell death or the induction of senescence in tumor cells, with the latter being completely eliminated by senolytics. The occurrence of high synergy upon inhibitor cotreatment was also tested on human colorectal cancer organoids and 119 different tumor cell lines. These experiments revealed highly synergistic activity of the compounds in one third of the tested tumor cell lines, which show statistically significant correlations with alterations in genes with known roles in metabolic regulation.

ORGANISM(S): Homo sapiens

PROVIDER: GSE285726 | GEO | 2025/05/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Discovery of BMS-986408, a First-In-Class Dual DGK⍺ and DGK Inhibitor That Unleashes PD-1 Checkpoint and CAR-T Cell Immunotherapies

Project description:DGKα and DGKζ are lipid kinases that negatively regulate T cell signaling through diacylglycerol (DAG) metabolism, making them attractive targets for next-generation immunotherapy. Here, we disclose the discovery and pre-clinical characterization of the first clinical-stage DGKα and DGKζ lipid kinase inhibitor, BMS-986408. BMS-986408 binds to the accessory subdomain of the catalytic domain and inhibits DGKα/ζ through a mechanism of action that includes DAG-substrate competitive inhibition, subcellular translocation to plasma membrane, and proteosome-dependent degradation. DGKα/ζ inhibition markedly improved the therapeutic benefit of PD-1 therapy by unleashing T cell responses in the tumor while also uniquely amplifying the priming and expansion of tumor-reactive T cells in the tumor-draining lymph nodes. Importantly, simultaneous inhibition of both DGKα and DGKζ was required to maximize combination benefit with PD-1 therapy. DGKα and DGKζ were broadly expressed in NSCLC tumor-infiltrated T cells and combination therapy invigorated a robust cytokine response in NSCLC patient-derived organotypic tumors supporting the clinical evaluation of this combination in NSCLC patients. BMS-986408 also markedly improved CD19-targeted CAR-T cell therapy efficacy by overcoming hypo-functionality, insufficient expansion, and lack of co-stimulatory ligands. BMS-986408 represents the first critical step towards evaluating the broad immunotherapy potential of DGKα/ζ inhibitors in cancer patients.

2025-04-04 | GSE293295 | GEO

The BET inhibitor GNE-987 effectively induces anti-cancer effects byfocusing on super-enhancers inT-cell acute lymphoblastic leukemia [Cut & Tag]

Project description:T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematologic malignant tumor that arises from T progenitor cells and accounts for 15% of childhood ALL and 25% of adult ALL cases. GNE-987 is a new chimeric molecule designed by proteolysis-targeting chimeras (PROTAC) technology. that combines an effective bromodomains and extra-targeting (BET) protein inhibitor with E3 ubiquitin ligase VHL(Von Hippel Lindau) and effectively induces proteasomal degradation of bromodomain-containing protein 4 (BRD4). GNE-987 and persistently inhibits cell proliferation and induces apoptosis, however, its anti-tumor activity GNE-987 in T-ALL has not been clarified, Here, we explore the molecular mechanisms underlying GNE-987's anti-tumor effect in T-ALL using RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP seq) and Cut&Tag technology.

2025-05-17 | GSE233299 | GEO

The BET inhibitor GNE-987 effectively induces anti-cancer effects by focusing on super-enhancers in T-cell acute lymphoblastic leukemia [RNA-Seq]

2025-05-17 | GSE232708 | GEO

Triple Isozyme Lactic Acid Dehydrogenase Inhibition using GNE-140 in Fully Viable Breast Cancer Cells induces Cytostatic Effects which are not-reversed by exogenous Lactic Acid

Project description:The effects of GNE-140 (50uM), on MDA-MB-231 cells evaluated by whole transcriptome: including mRNAs and long intergenic non-coding RNA transcripts using GeneChip™ Human Gene 2.1 ST Arrays by Affymetrix Inc.

2021-11-20 | GSE189183 | GEO

Sirt2 Inhibition Reprograms T Cell Metabolism to Confer Superior Anti-Tumor Immunity

Project description:Dysregulated metabolism is a key driver of maladaptive tumor-reactive T lymphocytes within the tumor microenvironment (TME). Actionable mechanisms that rescue the effector activity of anti-tumor T cells in a metabolically restricted TME remain elusive. Here, we report that the Sirtuin-2 (Sirt2) protein deacetylase functions as a master metabolic checkpoint that inhibits T cell metabolic fitness and impairs T cell effector functions and anti-tumor immunity. Mechanistically, Sirt2 suppresses glycolysis and oxidative-phosphorylation (OxPhos) by deacetylating key enzymes involved in glycolysis, tricarboxylic acid (TCA)-cycle, fatty acid oxidation (FAO) and glutaminolysis. Accordingly, Sirt2-deficient T cells exhibit a hyper-metabolic activity with increased glycolysis and OxPhos, resulting in enhanced proliferation and effector functions at tumor beds and subsequently exhibiting superior anti-tumor activity. Importantly, pharmacologic inhibition of Sirt2 endows human lung tumor-infiltrating lymphocytes (TILs) with these superior metabolic fitness and enhanced effector functions. Furthermore, upregulation of Sirt2 expression in human TILs negatively correlates with response to Nivolumab and TIL therapy in non-small cell lung cancer (NSCLC). Our findings unveil Sirt2 as an unexpected actionable target for reprogramming T cell metabolism to augment a broad spectrum of cancer immunotherapies.

2020-06-16 | PXD019763 | Pride

Transcriptomic profiling of MDA-MB-231 cells treated with cytostatic compounds

Project description:Transcriptomic profiling of MDA-MB-231 cells treated with Paclitaxel , 4-ethyl-N-(7-hydroxy-3,4-dihydroisoquinolin-2-(1H)-yl)benzamide (GM-453) or LDHAB inhibitor (6R)-3-[(2-Chlorophenyl)thio]-5,6-dihydro-4-hydroxy-6-[4-(4-morpholinyl)phenyl]-6-(3-thienyl)-2(1H)-pyridinone, (R)-3-(2-Chlorophenyl)sulfanyl-6-(4-morpholinophenyl)-6-(3-thienyl)piperidine-2,4-dione (GNE-140)

2020-12-12 | GSE163046 | GEO

UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE) is an inducer of apoptotic processes in Capan-1 pancreatic carcinoma cells: GNE silencing

Project description:Early invasive growth and metastasis are features of pancreatic cancer that rely on resistance to anoikis, an apoptosis program activated upon loss of adequate matrix anchorage. Re-expression of the tumor suppressor p16 reversed anoikis resistance of pancreatic cancer cells. This conversion to an anoikis-susceptible phenotype was found to be associated with a striking loss of GNE mRNA expression, prompting us to address the role of GNE in pancreatic cancer in more detail. GNE catalyzes a rate-limiting key step of the sialic acid biosynthesis and may have additional functions in the nucleus. Pancreatic cancer cells Capan-1. Three GNE-silencing samples and three control samples.

2010-08-01 | E-GEOD-22336 | biostudies-arrayexpress

Impaired stability of tumor cells after targeting of lactate/pyruvate metabolism investigated by shotgun proteomics

Project description:Overexpression of heat shock proteins (HSPs), especially the major stress-inducible 72 kDa heat shock protein 70 (Hsp70), in malignant tumor cells is associated with therapeutic resistance. The heightened metabolic demand in tumor cells (Warburg effect) increases lactate dehydrogenase (LDH) activity and the corresponding increase in lactate concentrations promotes malignancy. Herein, we assessed the co-regulation of LDH and the heat shock response and its link to radiation resistance in B16F10 murine melanoma cells and LS174T human colorectal adenocarcinoma cells. Inhibition of LDHA/B by oxamate or GNE-140, significantly diminishes the expression of Hsp90, Hsp70 and Hsp27 in the cytosol. Diminished expression was also observed in LDHA/B double knockout (LDH-/-) cells. An increased production of reactive oxygen species (ROS) induced by a faster growth rate in wild type (WT) vs LDH-/- cells contributes to increased cytosolic HSP levels in WT cells. LDH-/- cells exhibit a lower density of membrane Hsp70 expression than WT cells and a decreased presence of the tumor-specific, Hsp70 anchoring glycosphingolipid Gb3 on the cell surface which could be attributed to an altered lipid metabolism mediated by the LDH knockout. Functionally, a double knockout of LDHA/B results in a generalized reduction in expression of HSPs in tumor cells and significantly increases radiosensitivity which is associated with a G2/M arrest. In summary, we demonstrate that pharmacological targeting of the lactate/pyruvate metabolism breaks radioresistance by impairing the stress response.

2022-02-17 | PXD026078 | Pride

Induction of apoptotic processes in Capan-1 pancreatic carcinoma cells by restoration of p16INK4a expression

2010-08-01 | E-GEOD-22334 | biostudies-arrayexpress

Esculetin inhibits cancer cell glycolysis by binding tumor PGK2, GPD2, and GPI

Project description:Esculetin inhibits cancer cell glycolysis by binding tumor PGK2, GPD2, and GPI

| PRJNA599568 | ENA